Survodutide and Tirzepatide are both Metabolic peptides, but they're studied for different things. In short, Survodutide is an investigational GLP-1/glucagon dual agonist studied for weight and liver health, while Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for diabetes and weight management. This page compares the two side by side — what each is researched for, how mature the evidence is, and how they're typically used — so you can see where they overlap and where they differ. It's educational information only, not medical advice, and neither is a substitute for a conversation with a licensed professional.
Survodutide vs Tirzepatide at a glance
| Survodutide | Tirzepatide | |
|---|---|---|
| Category | Metabolic | Metabolic |
| In short | An investigational GLP-1/glucagon dual agonist studied for weight and liver health. | A dual GIP/GLP-1 receptor agonist approved for diabetes and weight management. |
| Researched for | Weight management, Liver health (MASH), Metabolic health | Blood sugar regulation, Weight management, Metabolic health |
| Research status | Clinical trials — investigational. | FDA-approved with large-scale human clinical trials. |
| Typically stacked with | — | — |
| Key consideration | Not approved. Investigational compound; use only under medical supervision. | Prescription medication with known side effects. Use only under medical supervision. |
How does Survodutide work?
Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors. Combining appetite regulation with glucagon-driven energy expenditure, it is under study for obesity and for metabolic-associated fatty liver disease (MASH).
How does Tirzepatide work?
Tirzepatide is a "dual agonist" that activates both the GIP and GLP-1 receptors. Engaging two incretin pathways appears to produce strong effects on appetite, blood sugar, and body weight, and it is FDA-approved for type 2 diabetes and chronic weight management.
Survodutide vs Tirzepatide: how to choose
Choosing between Survodutide and Tirzepatide really comes down to your specific goal — and it's a decision for you and a licensed professional, not something to settle from a web page. Survodutide is most associated with Weight management and Liver health (MASH), while Tirzepatide leans toward Blood sugar regulation and Weight management. Where they overlap, the practical differences are usually in mechanism and how far the research has actually progressed. Selpho provides no dosing or protocols; if you'd like a research-backed steer for your goals, the free Peptide Advisor is a good starting point.
Frequently asked questions
Both are Metabolic peptides. Survodutide is an investigational GLP-1/glucagon dual agonist studied for weight and liver health; Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for diabetes and weight management. They're most researched for Weight management, Liver health (MASH) (Survodutide) and Blood sugar regulation, Weight management (Tirzepatide), respectively.
There's no universal "better" — it depends on your goal, and for most of these compounds robust head-to-head human evidence doesn't exist. The right choice is one made with a licensed professional. Selpho does not rank or prescribe; it offers educational information and a research-backed advisor.
They're in the same category, and combining research compounds is something to approach only with a licensed professional, since interactions and individual context matter. Selpho provides no dosing or protocols.
Survodutide: Clinical trials — investigational. Tirzepatide: FDA-approved with large-scale human clinical trials.
Not sure which fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis comparison is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.